|
1
|
Hunter KW, Crawford NP and Alsarraj J:
Mechanisms of metastasis. Breast Cancer Res. 10 Suppl 1:S22008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang L, Riethdorf S, Wu G, Wang T, Yang
K, Peng G, Liu J and Pantel K: Meta-analysis of the prognostic
value of circulating tumor cells in breast cancer. Clin Cancer Res.
18:5701–5710. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Smith HA and Kang Y: The
metastasis-promoting roles of tumor-associated immune cells. J Mol
Med. 91:411–429. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wong CW, Lee A, Shientag L, Yu J, Dong Y,
Kao G, Al-Mehdi AB, Bernhard EJ and Muschel RJ: Apoptosis: An early
event in metastatic inefficiency. Cancer Res. 61:333–338.
2001.PubMed/NCBI
|
|
5
|
Baccelli I, Schneeweiss A, Riethdorf S,
Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T,
Wallwiener M, et al: Identification of a population of blood
circulating tumor cells from breast cancer patients that initiates
metastasis in a xenograft assay. Nat Biotechnol. 31:539–544. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Santos MF, Mannam VK, Craft BS, Puneky LV,
Sheehan NT, Lewis RE and Cruse JM: Comparative analysis of innate
immune system function in metastatic breast, colorectal, and
prostate cancer patients with circulating tumor cells. Exp Mol
Pathol. 96:367–374. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Noman MZ, Messai Y, Muret J, Hasmim M and
Chouaib S: Crosstalk between CTC, immune system and hypoxic tumor
microenvironment. Cancer Microenviron. 7:153–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim ST, Jeong H, Woo OH, Seo JH, Kim A,
Lee ES, Shin SW, Kim YH, Kim JS and Park KH: Tumor-infiltrating
lymphocytes, tumor characteristics, and recurrence in patients with
early breast cancer. Am J Clin Oncol. 36:224–231. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Al-Saleh K, Abd El-Aziz N, Ali A, Abozeed
W, Abd El-Warith A, Ibraheem A, Ansari J, Al-Rikabi A, Husain S and
Nabholtz JM: Predictive and prognostic significance of
CD8+ tumor-infiltrating lymphocytes in patients with
luminal B/HER 2 negative breast cancer treated with neoadjuvant
chemotherapy. Oncol Lett. 14:337–344. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mahmoud SM, Paish EC, Powe DG, Macmillan
RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-infiltrating
CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin
Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pagès F, Kirilovsky A, Mlecnik B, Asslaber
M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P,
et al: In situ cytotoxic and memory T cells predict outcome in
patients with early-stage colorectal cancer. J Clin Oncol.
27:5944–5951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dunn GP, Bruce AT, Ikeda H, Old LJ and
Schreiber RD: Cancer immunoediting: From immunosurveillance to
tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang J, Yang Z, Wang Z, Li Z, Li H, Yin J,
Deng M, Zhu W and Zeng C: Foxp3 is correlated with VEGF-C
expression and lymphangiogenesis in cervical cancer. World J Surg
Oncol. 15:1732017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Linehan DC and Goedegebuure PS: CD25+CD4+
regulatory T-cells in cancer. Immunol Res. 32:155–168. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ménétrier-Caux C, Gobert M and Caux C:
Differences in tumor regulatory T-cell localization and activation
status impact patient outcome. Cancer Res. 69:7895–7898. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bates GJ, Fox SB, Han C, Leek RD, Garcia
JF, Harris AL and Banham AH: Quantification of regulatory T cells
enables the identification of high-risk breast cancer patients and
those at risk of late relapse. J Clin Oncol. 24:5373–5380. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mahmoud SM, Paish EC, Powe DG, Macmillan
RD, Lee AH, Ellis IO and Green AR: An evaluation of the clinical
significance of FOXP3+ infiltrating cells in human breast cancer.
Breast Cancer Res Treat. 127:99–108. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gobert M, Treilleux I, Bendriss-Vermare N,
Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I,
Olive D, et al: Regulatory T cells recruited through CCL22/CCR4 are
selectively activated in lymphoid infiltrates surrounding primary
breast tumors and lead to an adverse clinical outcome. Cancer Res.
69:2000–2009. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu F, Lang R, Zhao J, Zhang X, Pringle
GA, Fan Y, Yin D, Gu F, Yao Z and Fu L: CD8+ cytotoxic T
cell and FOXP3+ regulatory T cell infiltration in
relation to breast cancer survival and molecular subtypes. Breast
Cancer Res Treat. 130:645–655. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang ZK, Yang B, Liu H, Hu Y, Yang JL, Wu
LL, Zhou ZH and Jiao SC: Regulatory T cells increase in breast
cancer and in stage IV breast cancer. Cancer Immunol Immunother.
61:911–916. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Andergassen U, Kölbl AC, Mahner S and
Jeschke U: Real-time RT-PCR systems for CTC detection from blood
samples of breast cancer and gynaecological tumour patients
(Review). Oncol Rep. 35:1905–1915. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chong MH, Zhao Y, Wang J, Zha XM, Liu XA,
Ling LJ, Du Q and Wang S: The dynamic change of circulating tumour
cells in patients with operable breast cancer before and after
chemotherapy based on a multimarker QPCR platform. Br J Cancer.
106:1605–1610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mikhitarian K, Martin RH, Ruppel MB,
Gillanders WE, Hoda R, del Schutte H, Callahan K, Mitas M and Cole
DJ: Detection of mammaglobin mRNA in peripheral blood is associated
with high grade breast cancer: Interim results of a prospective
cohort study. BMC Cancer. 8:552008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mego M, Gao H, Cohen EN, Anfossi S,
Giordano A, Tin S, Fouad TM, De Giorgi U, Giuliano M, Woodward WA,
et al: Circulating tumor cells (CTCs) are associated with
abnormalities in peripheral blood dendritic cells in patients with
inflammatory breast cancer. Oncotarget. 8:35656–35668. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mego M, Gao H, Cohen EN, Anfossi S,
Giordano A, Sanda T, Fouad TM, De Giorgi U, Giuliano M, Woodward
WA, et al: Circulating tumor cells (CTC) are associated with
defects in adaptive immunity in patients with inflammatory breast
cancer. J Cancer. 7:1095–1104. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Benoy IH, Elst H, Philips M, Wuyts H, Van
Dam P, Scharpé S, Van Marck E, Vermeulen PB and Dirix LY: Real-time
RT-PCR detection of disseminated tumour cells in bone marrow has
superior prognostic significance in comparison with circulating
tumour cells in patients with breast cancer. Br J Cancer.
94:672–680. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zamarron BF and Chen W: Dual roles of
immune cells and their factors in cancer development and
progression. Int J Biol Sci. 7:651–658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kallergi G, Politaki E, Alkahtani S,
Stournaras C and Georgoulias V: Evaluation of isolation methods for
circulating tumor cells (CTCs). Cell Physiol Biochem. 40:411–419.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Curiel TJ: Tregs and rethinking cancer
immunotherapy. J Clin Invest. 117:1167–1174. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Krishnamurthy S, Cristofanilli M, Singh B,
Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A,
Jackson S, et al: Detection of minimal residual disease in blood
and bone marrow in early stage breast cancer. Cancer.
116:3330–3337. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen Y, Zou TN, Wu ZP, Zhou YC, Gu YL, Liu
X, Jin CG and Wang XC: Detection of cytokeratin 19, human
mammaglobin, and carcinoembryonic antigen-positive circulating
tumor cells by three-marker reverse transcription-PCR assay and its
relation to clinical outcome in early breast cancer. Int J Biol
Markers. 25:59–68. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zou W: Regulatory T cells, tumour immunity
and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu S, Foulkes WD, Leung S, Gao D, Lau S,
Kos Z and Nielsen TO: Prognostic significance of FOXP3+
tumor-infiltrating lymphocytes in breast cancer depends on estrogen
receptor and human epidermal growth factor receptor-2 expression
status and concurrent cytotoxic T-cell infiltration. Breast Cancer
Res. 16:4322014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
West NR, Kost SE, Martin SD, Milne K,
Deleeuw RJ, Nelson BH and Watson PH: Tumour-infiltrating FOXP3+
lymphocytes are associated with cytotoxic immune responses and good
clinical outcome in oestrogen receptor-negative breast cancer. Br J
Cancer. 108:155–162. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liyanage UK, Moore TT, Joo HG, Tanaka Y,
Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ,
Goedegebuure PS, et al: Prevalence of regulatory T cells is
increased in peripheral blood and tumor microenvironment of
patients with pancreas or breast adenocarcinoma. J Immunol.
169:2756–2761. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li CH, Kuo WH, Chang WC, Huang SC, Chang
KJ and Sheu BC: Activation of regulatory T cells instigates
functional down-regulation of cytotoxic T lymphocytes in human
breast cancer. Immunol Res. 51:71–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chiba T, Ohtani H, Mizoi T, Naito Y, Sato
E, Nagura H, Ohuchi A, Ohuchi K, Shiiba K, Kurokawa Y and Satomi S:
Intraepithelial CD8+ T-cell-count becomes a prognostic factor after
a longer follow-up period in human colorectal carcinoma: Possible
association with suppression of micrometastasis. Br J Cancer.
91:1711–1717. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Campbell MJ, Scott J, Maecker HT, Park JW
and Esserman LJ: Immune dysfunction and micrometastases in women
with breast cancer. Breast Cancer Res Treat. 91:163–171. 2005.
View Article : Google Scholar : PubMed/NCBI
|
